A Multicenter, Vehicle-controlled, Double-Masked, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of AGN-242428 and AGN-231868 in Participants With Dry Eye Disease

2012-201-005

This will be a 2 stage study in which Stage 1 will evaluate the safety of AGN-242428 and AGN-231868, how well they are tolerated and how they move through the body when administered. After the sponsor's determination of adequate safety and tolerability of the interventions in Stage 1, Stage 2 will begin. Stage 2 will also evaluate the safety and tolerability of AGN-242428 and AGN-231868, how effective they are in treating dry eye disease and assess the plasma and tear exposure of both ophthalmic solutions.

2020-03-04

2022-03-18

2022-03-18

Completed

Early phase I

292

Inclusion Criteria: Stage 1 \& Stage 2 * Male participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study; * Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study; * Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol; Stage 1 * Both of the following signs of DED in at least 1 eye at Screening and Baseline visits (the same eye does not need to qualify at both visits); * Total corneal fluorescein staining score ≥ 2 and ≤ 9 based on the NEI grading scale, with no score \> 2 in any 1 region; * Schirmer test with topical anesthesia score ≥ 1 and ≤ 10 mm/5 min; Stage 2 * ALL of the following in at least 1 eye at both the Screening and Baseline visits and the same eye must qualify at both Screening and Baseline visits; * Corneal fluorescein staining score ≥ 2 in at least 1 eye region and a total corneal fluorescein staining score of ≥ 4 and ≤ 12 based on NEI grading scale * Schirmer test with topical anesthesia score ≥ 2 and ≤ 10 mm/5 min; * Mean TBUT of ≥ 2 and ≤ 10 seconds Stage 1 * Symptoms of DED at both the Screening and Baseline visits as defined by an OSDI total score of ≥ 13 with ≤ 3 responses of "not applicable (NA)"; Stage 2; * Symptoms of DED at both the Screening and Baseline visits as defined by both: * OSDI score of ≥ 23 with ≤ 3 responses of "not applicable (NA)" in at least 1 eye; * Eye Dryness Score (assessed using the Visual Analog Scale (VAS) Symptom Items score ≥ 30 Exclusion Criteria: * Current diagnosis of glaucoma or ocular hypertension; evidence of glaucoma or mean intraocular pressure \> 21 mm Hg determined by Goldmann applanation tonometry, in either eye; * Diagnosis of recurrent, ongoing, or active ocular infection including, but not limited to herpes simplex or zoster, vaccinia, varicella, tuberculosis of the eye, acanthamoeba, or fungal disease; * Participation in a blood or plasma donation program within 60 or 30 days, respectively, prior to study intervention administration; * Positive test results for anti-HIV type 1 and 2, hepatitis B surface antigen, or anti-hepatitis C virus at the Screening visit; * Positive test results for benzoylecgonine (cocaine), methadone, barbiturates, amphetamines, benzodiazepines, alcohol, cannabinoids, opiates, or phencyclidine at the Screening or Baseline visits; * Positive pregnancy test at Screening or Baseline visits; * Currently breastfeeding or plans to breastfeed during the study; * History or presence of any ocular disorder or condition (other than DED) in either eye that would, in the opinion of the investigator, likely interfere with the interpretation of the study results or participant safety.

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 292, 'type': 'ACTUAL'}}

2023-03-20